• C L Zuur, Y J W Simis, P E M Lansdaal, Rasch C R N CR, R A Tange, A J M Balm, and W A Dreschler.
• Department of Otorhinolaryngology, Academical Medical Centre Amsterdam, Amsterdam, The Netherlands. cl.zuur@vumc.nl
• Audiol. Neurootol. 2006 Jan 1; 11 (5): 318-30.

AbstractThis study describes audiometric patterns of ototoxicity in a consecutive series of patients uniformly treated with intra-arterial high-dose cisplatin chemoirradiation for advanced cancer of the head and neck. Air conduction thresholds were measured from 0.125 to 16 kHz and bone conduction thresholds were measured from 0.5 to 4 kHz. The overall audiometric pattern was characterized by maximum threshold shifts after the 2nd cisplatin infusion and a maximum total threshold shift at 8 kHz, irrespective of gender, age, pretreatment sensorineural hearing loss (SNHL) or subjective complaints during therapy. A hearing deterioration gradient was observed from (ultra-) high to low frequencies, worse with increasing pre-existent SNHL and with increasing cumulative dose of cisplatin chemoradiation. Cisplatin chemoradiation-induced hearing loss seemed to reach a plateau at higher levels (75-80 dB HL) for frequencies above 8 kHz compared to frequencies up to 8 kHz (45-60 dB HL). Recovery of SNHL was found after therapy in 27 ears characterized by extensive hearing loss at frequencies 1, 2 and 4 kHz.Copyright 2006 S. Karger AG, Basel.

34 keywords...

hide…